Avastin Needs Quality Of Life Data In Confirmatory Glioblastoma Trial – Cmte.
Executive Summary
Quality of life issues could be incorporated into a Phase III confirmatory study for Genentech's Avastin in treatment of glioblastoma multiforme, following suggestions by members of FDA's Oncologic Drugs Advisory Committee
You may also be interested in...
Avastin QoL Data In First-Line Glioblastoma Muddy Expansion Plans
Genentech’s bevacizumab was associated with improved maintenance of baseline quality of life and performance status in a confirmatory trial conducted under accelerated approval, but an NCI-funded study found higher rates of neurocognitive decline, increased symptom severity and decline in health-related quality of life.
R&D Realities Disturb Dreams About Orphan Brain Cancer Blockbusters
Developing drugs for the rare, aggressive glioblastoma, the most common and malignant type of glioma, or brain cancer, was never easy. But a brain cancer drug’s journey through Phase III and to the finish line of market entry today is more arduous than ever.
R&D Realities Disturb Dreams About Orphan Brain Cancer Blockbusters
Developing drugs for the rare, aggressive glioblastoma, the most common and malignant type of glioma, or brain cancer, was never easy. But a brain cancer drug’s journey through Phase III and to the finish line of market entry today is more arduous than ever.